Health & Fitness
Health and Fitness
Health and Fitness
Mon, May 24, 2010 
NEWARK, Del.--([ BUSINESS WIRE ])--SDIX (Nasdaq: SDIX), a leading provider of biotechnology-based products and services for a broad range of life science, biotechnology, diagnostic and food safety applications, today announced that Wayne P. Yetter has been elected to the Board of Directors, effective May 18, 2010. Mr. Yetter is a member of Class II of the SDIXboard and his term is scheduled to expire at the annual meeting of stockholders to be held in 2012.
"His years of leadership experience in the Life Science industry will add knowledge and insight to the SDIX board and to our management team. We look forward to his contributions as we continue to work to transition SDIX into a growth business."
Mr. Yetter is currently Chief Executive Officer of ProActive for Patients Media, Inc., an early investment stage company providing a physician-to-patient messaging system to increase patient adherence to medication therapies. Previously, Mr. Yetter served as Chief Executive Officer of Verispan LLC, a joint venture of McKesson Corp. and Quintiles Transnational, a leading provider of healthcare information and marketing services to the pharmaceutical industry. Mr. Yetter has had a 30 year career in the pharmaceutical industry and held executive positions at Pfizer, Merck, Astra-Merck (now AstraZeneca) and Novartis. His roles included Vice President, Marketing Operations (global) and Vice President, Far East and Pacific at Merck, founding Chief Executive Officer of Astra-Merck, and President and Chief Executive Officer of Novartis Pharmaceuticals Corporation, the US division of Novartis AG. Mr. Yetter holds a B.A. in Biology from Wilkes University and received an M.B.A from Bryant University.
aWe are excited to welcome Wayne to the SDIX board,a said Fran DiNuzzo, President and CEO of SDIX. aHis years of leadership experience in the Life Science industry will add knowledge and insight to the SDIX board and to our management team. We look forward to his contributions as we continue to work to transition SDIX into a growth business.a
About SDIX
SDIX is a biotechnology company, expert at creating advantage by providing a broad range of quality, innovative and effective immuno-solutions to the Pharmaceutical, Biotechnology, Diagnostics, and Food Safety markets. For 20 years, SDIX has developed antibodies which advance its customersa™ immuno-based work a" reducing time, labor, and costs while increasing accuracy and reliability of results.
SDIX offers a full suite of integrated immuno-solution capabilities including assay design, development, and production. In life science markets, SDIX capabilities are being used to help discover the mechanisms of disease, facilitate the development of new drugs, and provide mechanisms for rapid diagnosis. For more information, visit [ www.sdix.com ].
This news release may contain forward-looking statements reflecting SDI's current expectations. When used in this press release, words like aanticipatea, acoulda, aenablea, aestimatea, aintenda, aexpecta, abelievea, apotentiala, awilla, ashoulda, aprojecta, aplana and similar expressions as they relate to SDI are intended to identify said forward-looking statements. Investors are cautioned that all forward-looking statements involve risks and uncertainties, which may cause actual results to differ from those anticipated by SDI at this time. Such risks and uncertainties include, without limitation, changes in demand for products, the application of our technologies to various uses, delays in product development, delays in market acceptance of new products, retention of customers and employees, adequate supply of raw materials, inability to obtain or delays in obtaining fourth party, including AOAC, or required government approvals, the ability to meet increased market demand, competition, protection of intellectual property, non-infringement of intellectual property, seasonality, and other factors more fully described in SDI's public filings with the U.S. Securities and Exchange Commission.
